MedTrace Logo

Study of AZD8931 in Patients With Advanced Solid Malignancies

NCT00637039 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-03-12

No results posted yet for this study

Summary

The main purpose of this study is to explore the safety and tolerability of multiple ascending doses (MAD) of AZD8931 in patients with advanced solid malignancies

Conditions

  • Advanced Solid Malignancies

Interventions

DRUG

AZD8931

Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.

Sponsors & Collaborators

Principal Investigators

  • S. Tjulandin · GU Russian Oncology Research Centre

  • Serban Ghiorghiu · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2009-06-30
Completion
2012-12-31

Countries

  • Germany
  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00637039 on ClinicalTrials.gov